Oppenheimer Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Oppenheimer Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$664K	Sell	1,236 -91	-7%	-$46.6K	0.01%	825
2026 Q1	$695K	Buy	1,327 +14	+1%	+$6.69K	0.01%	808
2025 Q4	$765K	Buy	1,313 +207	+19%	+$106K	0.01%	735
2025 Q3	$507K	Sell	1,106 -14	-1%	-$5.22K	0.01%	895
2025 Q2	$339K	Sell	1,120 -83	-7%	-$24.7K	﹤0.01%	959
2025 Q1	$398K	Buy	1,203 +71	+6%	+$23.3K	﹤0.01%	909
2024 Q4	$349K	Sell	1,132 -375	-25%	-$105K	﹤0.01%	956
2024 Q3	$320K	Buy	1,507 +31	+2%	+$7.93K	﹤0.01%	993
2024 Q2	$414K	Buy	+1,476	New	+$351K	0.01%	901

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Oppenheimer Asset Management's MDGL Position: Q2 2026 in Review

Oppenheimer Asset Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 6.9% in Q2 2026, selling an estimated $46.6K and leaving 1,236 shares worth $664K. The position accounts for 0.01% of the portfolio, ranked #825.

Oppenheimer Asset Management first reported a position in MDGL in Q2 2024 and has held it in 9 quarters since. The position peaked at $765K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Oppenheimer Asset Management held 1,236 shares of Madrigal Pharmaceuticals worth $664K as of Q2 2026.
Oppenheimer Asset Management sold 91 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $46.6K.
Madrigal Pharmaceuticals made up 0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #825 holding.
Oppenheimer Asset Management first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Oppenheimer Asset Management's Madrigal Pharmaceuticals position peaked at $765K in Q4 2025.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.